---
title: "Immunic to Participate in Investor, Industry and Scientific Conferences in June"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289314021.md"
description: "On June 10, 2026, Immunic, Inc. (Nasdaq: IMUX), a leading biotech firm focusing on advanced oral treatments for neurologic disorders, disclosed its involvement in various investor, industry, and scientific conferences happening this month. The company's participation in these events highlights its commitment to advancing medical innovation and sharing insights within the field. This aligns with Immunic's mission to address the unmet medical needs of patients. Through these engagements, Immunic aims to showcase its potential in transforming the treatment landscape for neurologic diseases."
datetime: "2026-06-10T10:33:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289314021.md)
  - [en](https://longbridge.com/en/news/289314021.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289314021.md)
generator: "portal-rs"
---

# Immunic to Participate in Investor, Industry and Scientific Conferences in June

On June 10, 2026, Immunic, Inc. (Nasdaq: IMUX), a leading biotech firm focusing on advanced oral treatments for neurologic disorders, disclosed its involvement in various investor, industry, and scientific conferences happening this month. The company's participation in these events highlights its commitment to advancing medical innovation and sharing insights within the field. This aligns with Immunic's mission to address the unmet medical needs of patients. Through these engagements, Immunic aims to showcase its potential in transforming the treatment landscape for neurologic diseases.

### Related Stocks

- [IMUX.US](https://longbridge.com/en/quote/IMUX.US.md)

## Related News & Research

- [Immunic, Inc. $IMUX Shares Acquired by Bank of America Corp DE](https://longbridge.com/en/news/298823755.md)
- [Immunic director Duane Nash resigns, board shrinks to nine members](https://longbridge.com/en/news/298771566.md)
- [Immunic hosts RMS R&D Day webinar, presents vidofludimus calcium program and forward-looking plans](https://longbridge.com/en/news/298462931.md)
- [IMUX: Pivotal Phase 3 data for vidofludimus calcium in relapsing MS expected by end of 2026](https://longbridge.com/en/news/298485112.md)
- [IMUX: Pivotal phase III data for vidofludimus calcium in relapsing MS expected by year-end, targeting NDA in 2025](https://longbridge.com/en/news/298495158.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**